Research
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4530 (Published 04 October 2017) Cite this as: BMJ 2017;359:j4530
Data supplement
Web Extra
- Data Supplement - Appendix: Supplementary material
Related articles
- Editorial Published: 04 October 2017; BMJ 359 doi:10.1136/bmj.j4528
- Feature Published: 04 October 2017; BMJ 359 doi:10.1136/bmj.j4543
- Editorial Published: 26 February 2018; BMJ 360 doi:10.1136/bmj.k840
- Analysis Published: 17 May 2018; BMJ 361 doi:10.1136/bmj.k1039
- Analysis Published: 10 July 2019; BMJ 366 doi:10.1136/bmj.l4340
- Editorial Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5399
- Research Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5221
- Letter Published: 15 October 2019; BMJ 367 doi:10.1136/bmj.l6017
- Analysis Published: 02 January 2020; BMJ 368 doi:10.1136/bmj.l6435
- Editorial Published: 10 March 2020; BMJ 368 doi:10.1136/bmj.m770
- Research Published: 04 November 2020; BMJ 371 doi:10.1136/bmj.m4087
See more
- NICE recommends new CAR-T treatment for lymphoma for some patients on NHSBMJ January 20, 2021, 372 n184; DOI: https://doi.org/10.1136/bmj.n184
- NHS should vary price it pays for cancer drugs to improve access, say expertsBMJ November 09, 2020, 371 m4322; DOI: https://doi.org/10.1136/bmj.m4322
- Colon cancer screening should begin at 45, says US task forceBMJ October 29, 2020, 371 m4188; DOI: https://doi.org/10.1136/bmj.m4188
- Leading oncologist faces GMC allegations of inappropriate treatment of dying patientsBMJ September 15, 2020, 370 m3594; DOI: https://doi.org/10.1136/bmj.m3594
- Covid-19: Waiting times in England reach record highsBMJ September 11, 2020, 370 m3557; DOI: https://doi.org/10.1136/bmj.m3557
Cited by...
- Mortality due to cancer treatment delay: systematic review and meta-analysis
- Designed nanomolar small-molecule inhibitors of Ena/VASP EVH1 interaction impair invasion and extravasation of breast cancer cells
- FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)
- Real-world Drug Regimens for Multiple Myeloma in a Swiss Population (2012 to 2017): cost-outcome description
- Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system
- Inappropriate use of progression-free survival in cancer drug approvals
- How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
- EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
- Flawed evidence underpins approval of new cancer drugs
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- New drugs: where did we go wrong and what can we do better?
- Ab-initio discovery of tumoricidal oligonucleotides in a DNA sequencing machine
- Discovery of tumoricidal DNA oligonucleotides by effect-directed in-vitro evolution
- On fitness: how do mutations shape the biology of cancer?
- Biomarkers for capturing disease pathology as molecular process hyperstructure
- Premarket evaluation of medical devices: a cross-sectional analysis of clinical studies submitted to a German ethics committee
- Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer
- Detection of a novel, primate-specific 'kill switch tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53
- Pathways to faster access to medicines
- Choosing wisely in oncology: necessity and obstacles
- Conflict of interest among Italian medical oncologists: a national survey
- Healing an ailing pharmaceutical system: prescription for reform for United States and Canada
- Removing the blindfold on medicines pricing
- Outcomes for cancer drugs approved in Europe
- Cancer drugs: high price, uncertain value
- Do cancer drugs improve survival or quality of life?